Astellas Pharma | 4503

Astellas Pharma traded at 1,866.00 this Wednesday March 22nd, increasing 33.50 or 1.83 percent since the previous trading session. Looking back, over the last four weeks, Astellas Pharma gained 2.10 percent. Over the last 12 months, its price fell by 6.63 percent. Looking ahead, we forecast Astellas Pharma to be priced at 1,794.43 by the end of this quarter and at 1,636.21 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
1,866.00
Daily Change
1.83%
Yearly
-6.63%

Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

API Features Documentation Interested? Click here to contact us
Please Paste this Code in your Website
width
height
 Preview
Peers Price Day Year
M3 Inc 3,391.00 14.00 0.41% -22.98%
Kyowa Hakko Kirin 2,846.00 32.00 1.14% -8.34%
Takeda 4,365.00 74.00 1.72% 20.58%
Astellas Pharma 1,866.00 33.50 1.83% -6.63%
Sumitomo Dainippon 800.00 9.00 1.14% -36.86%
Shionogi 5,948.00 88.00 1.50% -21.17%
Chugai Pharma 3,324.00 13.00 0.39% -19.61%
Eisai 7,315.00 87.00 1.20% 21.67%
Terumo 3,610.00 86.00 2.44% -6.38%
Daiichi Sankyo 4,670.00 181.00 4.03% 82.39%
Otsuka Holdings 3,958.00 40.00 1.02% -7.31%

Indexes Price Day Year
JP225 27467 520.94 1.93% -2.05%

Astellas Pharma
Astellas Pharma Inc is a Japan-based company mainly engaged in the research, development, manufacture and sales of pharmaceutical products. The Company mainly operates Pharmaceutical Products business segment. The main products include XTANDI, BETANIS, MIRABETRIC, BETMIGA and new products ZOSPATA, EVERENZO and ENHOLTUMAB VEDOTIN, among others.